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1. Introduction
  Hepatitis C virus (HCV) is a plus stranded RNA virus 
belonged to the family Flaviviridae. It has infected more 
than 200 million people worldwide with high morbidity and 
mortality[1]. World Health Organization reported in 2012 that 
the annual deaths caused by HCV related liver diseases are 
greater than 350 000[2]. Pakistan has more than 10 million 
people carrying HCV infection[1].
  HCV is classified into different genotypes on the basis of 
nucleotides sequence divergence. A strong link has been 
reported between viral genotypes and treatment response. 
HCV is classified into six genotypes[3]. HCV genotypes 1-3 
are prevalent throughout the world, and their prevalence 
varies from area to area. In Middle East and North Africa 
major prevalent HCV genotype is 4. HCV genotype 5 and 6 
are dominant in South Africa and Hong Kong respectively[4]. 
The major prevalent genotype in Pakistan is 3[3-6].
  The major objective of HCV therapy is to attain sustained 
virological response (SVR), which is defined as the absence 
of HCV RNA in serum after 6 months of treatment completion, 
confirmed by polymerase chain reaction (PCR)[7]. Two decades 
back, HCV treatment was started with recombinant human 
interferon alpha[8]. The interferon decreased the viral RNA 
in a considerable number of patients, but it also produces 
a number of side effects. Ribavirin is a purine analog of 
HCV. It has ability to increase the viral mutation rate to a 
level where viable genomes are only able to produce unfit 
progeny. Ribavirin down regulates the production of cellular 
IMP dehydrogenase enzyme, leading to decreased cellular 
GTP levels. It also modulates the host’s immune system and 
increases the polymerase mutation rate, leading to error 
catastrophe[9-13].
  Currently there is no vaccine available for HCV[14]. The 
only available treatment option for majority of genotypes 
is the combination of interferon and ribavirin. The therapy 
showed diverse response in patients living with different 
HCV genotypes along with a number of side effects. 
More than 10 million people are suffering from hepatitis C virus (HCV) in Pakistan. The available 
treatment option is a combination of interferon and ribavirin. Treatment response is linked with 
several factors and also induces a number of side effects. We searched in Pubmed, Pak Medi 
Net and Google Scholar for the articles presenting the effect of interferon plus ribavirin therapy 
on HCV patients from Pakistan, their side effects and future prospects. The major prevalent 
HCV genotype in Pakistan is 3. Conventional interferon alpha plus ribavirin showed sustained 
virological response of 54%-64% while pegylated interferon alpha plus ribavirin showed sustained 
virological response of 58%-75%. IL-28B CC genotype is linked with better sustained virological 
response. Studies on patients with HCV genotype 3 infections showed no correlation between 
treatment response and interferon sensitivity determining region mutations. Interferon therapy 
is linked with a number of side effects like thyroid dysfuncton, haematological disorders, weight 
loss, gastrointestinal tract side effects and neuropsychiatric side effects. Unusual side effects 
of clubbing of fingers and seizures were also observed in a couple of patients. Interferon alpha 
plus ribavirin therapy showed better response rate in HCV genotype 3 patients from Pakistan 
with number of side effects. A couple of interferon free therapies are light of hope for the patients 
living with HCV.
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Recently two protease inhibitors were approved by FDA 
for the treatment of patients living with HCV genotype 1 
infection. The protease inhibitors remained unsuccessful 
due to rapid emergence of resistant mutants[12]. This article 
presents the effect of different therapeutic combinations 
being used for the treatment of HCV patients living in 
Pakistan, side effects of therapy, factors linked with therapy 
response and future therapeutic prospects.
2. Literature search
  We searched in Pubmed, Google Scholar, Pak Medi Net and 
Google Web for the articles by using keywords “Effect of 
interferon treatment on HCV patients from Pakistan, Factors 
linked with interferon treatment response in Pakistan, 
side effects of interferon therapy and hepatitis C virus in 
Pakistan”. Inclusion criteria entailed the manuscripts with 
HCV treatment response and risk factors from reliable 
publication source, while the data without any references 
were excluded from the study.
3. Effect of conventional interferon plus ribavirin 
therapy
  Interferon alpha with ribavirin was administered to 616, 
HCV genotype 3, treatment naive patients for 24 weeks. SVR 
was achieved in 63.5% patients. Moreover, 70.7% response 
rate was achieved in female patients having age less than 40 
years compared with 55.4% response rate in female patients 
having age greater than 40 years. Similarly, male patients 
having age less than 40 years showed response rate of 67.3% 
compared with 53.9% in male patients of age greater than 
40 years. The patients having HCV RNA titer <8×105 
IU/mL showed response rate of 68.9% compared with 60.4% 
response rate in patients with HCV RNA titer >8×105 
IU/mL. The patient population was divided into two groups, 
ie., Punjabi and Pushtoon. Response rate was observed 
69.9% in Pushtoon patients compared with 62% in Punjabi 
patients[15].
  In another study by Ahmed et al, conventional interferon 
plus ribavirin was administered to 829 patients for 24 weeks 
to HCV genotypes 2 & 3 patients and for 48 weeks to HCV 
genotypes 1 & 4 patients. End-of-treatment response (ETR) 
was achieved in 74% of patients. Post treatment follow up 
was available in 492 patients. SVR was achieved in 63% 
(308 out of 492 cases) of patients. Better response rate was 
observed in patients with <40 years of age, serum 
albumin >4 g/dL, normal alanine aminotransferase at 
the first month of therapy, non-diabetic and with normal 
platelet count[16].
  Conventional interferon plus ribavirin was administered to 
86 patients enrolled at Ghurki Trust Hospital Lahore. Totally, 
69% of patients showed rapid virologic response (RVR) while 
SVR was observed in 53.5% patients. Younger age and RVR 
were important factors to achieve SVR. Male patients showed 
better SVR than female patients[17].
4. Effect of pegylated interferon plus ribavirin therapy
  In a study by Aziz et al, 403 HCV patients were 
administered pegylated interferon alpha-2b with ribavirin 
for 24 weeks to HCV genotype 3 patients and for 48 weeks 
to HCV genotype 1 patients. Overall SVR was achieved in 
74.7% patients. Patients having age <40 years showed SVR 
of 79% as compared with 69% in patients >40 years. Patients 
having viral load <8×105 IU/mL showed SVR of 85% as 
compared with 70% in patients having viral load >8×105 
IU/mL. SVR of 76% and 55% was observed in HCV genotype 
3 and HCV genotype 1 patients respectively. Ethnic group 
Pushtoon showed SVR of 85% compared with 73% SVR in 
Punjabi group. SVR was observed 86% in patients with 
RVR and 39% in non-RVR patients. The most common side 
effects observed were fever, headache, fatigue, myalgia, 
diarrhea and skin rash. Insomnia and depression were most 
commonly observed psychiatric side effect[18].
  In another study, 426 HCV genotype 3 patients were 
enrolled and pegylated interferon alpha-2a with ribavirin 
was administered for 24 weeks. Overall SVR was observed in 
75.1% of patients. The patients less <40 years showed SVR of 
80.8% compared with 69.1% SVR in patients >40 years of age. 
Male patients showed SVR of 78.5% while female patients 
showed SVR of 71.9%. Patients having HCV RNA <8×105 IU/mL 
showed SVR of 87.7% while patients with viral titer >8×105 
IU/mL showed SVR of 63.7%. The SVR was observed in 85.5% 
of RVR patients and 44.4% of non-RVR patients. Patients 
with normal alanine aminotransferase showed SVR of 85.5% 
while the patients with raised alanine aminotransferase 
showed SVR of 72.9%. The most common side effects 
observed were fatigue (in 55.2%), headache (in 16.2%), cough 
(10.3%), fever (in 12.2%) and alopecia (in 2.3%). Insomnia and 
depression were frequently observed psychiatric adverse 
effect[19].
  Chronic HCV cirrhotic patients are difficult to treat. Butt 
et al enrolled 66 HCV cirrhotic patients in her study. Out 
of 66 patients, 61 had child’s A cirrhosis and 5 had child’s 
B cirrhosis. All the patients belonged to HCV genotypes 3. 
About 50% of patients were given peg-interferon alpha-
2a with ribavirin and other 50% were given peg-interferon 
alpha-2b with ribavirin. Early virological response was 
achieved in 44 (66.7%) patients and ETR was achieved in 
46 (69.7%) patients. The overall SVR was observed in 38 
(57.6%) patients. Factors affecting SVR were patient’s age, 
treatment naive status and achievement of early virological 
response. Due to the development of neutropenia and 
anaemia, 10 patients required erythropoietin or GCSF during 
treatment[20].
5. IL-28B polymorphism
  Genome wide association studies showed that a genetic 
polymorphism on chromosome 19, at rs12979860, near IL28 
gene is linked with response to interferon therapy[21,22]. It 
has observed that genotype CC of IL-28B is linked with 2-3 
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folds rise in SVR as compared to CT or TT genotypes[23]. 
It is also reported that IL-28B patients with CC genotypes 
responded more quickly to treatment as compared with 
TC and TT genotypes. CC genotype was observed in 77% of 
patients with rapid virological response. This genotype also 
predicts SVR in patients who had not achieved RVR. IL-28B 
polymorphism is also a factor affecting peg-interferon and 
ribavirin therapy response[21-24].
6. Interferon sensitivity determining region 
  HCV variants with mutations in NS5A gene play a role in 
conferring interferon resistance and the region is known 
as interferon sensitivity determining region (ISDR). Several 
studies on patients having HCV genotype 1 showed ISDR 
mutations perturbing interferon therapy response[25-27]. 
Studies on HCV genotype 3 patients showed no correlation 
with ISDR mutations and interferon therapy response[28,29]. Ali 
et al studied HCV NS5A mutations and response to interferon 
therapy in genotype 3 patients. In this study he sequenced 
HCV NS5A gene before and after the therapy in 27 patients. 
SVR was achieved in 20 patients, 4 patients did not show 
any response while remaining 3 showed ETR. Three SVR 
patients and two ETR patients showed mutations (栺-桋 
amino acids) within the NS5A ISDR region. While 85% SVR 
and all NR has no mutations in ISDR region. They concluded 
that the mutations in NS5A region of HCV 3a genotypes may 
not influence the response rate of interferon plus ribavirin 
therapy in Pakistani patients[28].
7. Protein kinase (PKR) eukaryotic initiation factor 
2 alpha (eIF2a) phosphorylation homology domain 
(PePHD)
  During HCV infection, interferon is released from the 
infected cells and in response; the neighboring cells release 
PKR. During HCV replication, the viral single stranded RNA 
is converted into double stranded RNA. The double stranded 
RNA activates PKR, which leads to phosphorylation of eIF2a 
which halts the HCV RNA transcription. The HCV is a smart 
virus; it evolved a mechanism to overcome the host antiviral 
response. The HCV glycoprotein E2 carries a short stretch of 
12 amino acids, forming a domain known as PePHD, which 
binds with protein kinase leading to inhibition of interferon 
alpha resulting in viral persistence[30-32]. 
  The PePHD domain of six different HCV genotype 3 patients 
was compared. Three patients showed RVR and rest of three 
showed breakthrough to the same therapy. No conservation 
in PePHD domain was observed. Amino acid substitution of 
glutamine to leucine was observed in a non responder patient 
which made it more identical to HCV genotype 1a. This 
substitution also increased the average hydrophilic activity, 
making binding of PePHD to PKR more easy and inhibition 
of PKR more favorable[30].
8. Side effects of therapy 
  It is reported that the interferon plus ribavirin therapy 
leads to thyroid dysfunction in HCV patients. Nadeem et 
al gave combined therapy to HCV patients and analyzed 
thyroid functions at 0, 12 and 24 weeks. In total, 18.69% 
patients showed thyroid dysfunction with hypothyroidism 
being observed more common than hyperthyroidism. Thyroid 
dysfunction was observed higher in female patients. There 
was no association observed between severity of diseases 
and response to therapy with interferon induced thyroid 
dysfunction[33].
  Interferon and ribavirin therapy also induces various 
hematological disorders. In a study conducted at Liaquat 
University Jamshoro, 100 patients were give interferon and 
ribavirin therapy and their hematological parameters were 
analyzed. Significant drop in mean haemoglobin, mean total 
leucocyte count and mean platelates count was observed 
in majority of patients. About 38% patients developed 
anemia, 13% developed leucopenia and 17% developed 
thrombocytopenia at 24 weeks of therapy[34].
  Weight loss is also observed as side effect of interferon 
plus ribavirin therapy. In a study conducted at Jinnah 
Postgraduate Medical Center, Karachi, 260 patients were 
given interferon plus ribavirin therapy and their body weight 
was measured at 1, 3, 6 months of treatment and 6 months 
after the cessation of treatment. Weight loss was observed 
in 67.7% patients on completion of therapy compared with 
initial visit. Weight loss was observed to be independent of 
gender, age, treatment response, haemoglobin level, white 
blood cell counts and platelet counts. In most of the cases 
the body weight returned to baseline within 6 months after 
the completion of therapy[35]. 
  Mahmood et al gave interferon plus ribavirin therapy 
to 400 patients and carefully observed various mild to 
moderate and severe side effects. The mild to moderate side 
effects observed were leukopenia (64%), anaemia (70%) and 
thrombocytopenia (61%). Flu like symptoms, e.g., fever (70%), 
fatigue (67%), headache (62%), myalgia (54%) and arthralgia 
(34%), were also observed in large patient population. GIT 
side effects observed were loss of appetite (35%), dyspepsia 
(16%) and constipation (5%). Neuropsychiatric side effects 
observed were irritability (28%), depression (20%), insomnia 
(35%), anxiety (12%) and emotional instability (10%). Other 
side effects observed were rhinitis (10%), pharyngitis (8%), 
thyroid abnormality (4%) and retinopathy (8%). The severe 
side effects of therapy observed were severe anaemia (8%), 
severe neutropenia (3%), severe thrombocytopenia (1%), 
major depression (1%), suicide ideation (0.5%) and severe 
thyrotoxicosis (0.5%)[36].
9. Unusual effects 
  Peg-interferon plus ribavirin was administered to 4 913 
patients; eight had seizure. Five patients had unknown type 
of seizures, while three patients had grand mal seizure. It is 
also observed that six patients were taking anti-depressants 
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at the time of seizures, one patient had taken enough amount 
of alcohol and one was hyponatremic. It is concluded that 
seizures occur occasionally in patients on peg-interferon 
plus ribavirin therapy and are associated with the use of 
antidepressants[37].
  An unusual effect of clubbing of fingers was observed in 
two patients on interferon alpha plus ribavirin therapy. One 
patient developed clubbing of fingers in the second month of 
therapy and the other patient developed in the fourth month 
of therapy. Clubbing was bilateral, of grad 栻 in one patient 
and grade 栿 in another. Clubbing was not observed before 
the start of therapy and no other secondary cause was seen. 
Both patients were not taking any other drug which interferes 
with therapy or can be associated with clubbing[38].
10. Future prospects
  In addition to peg-interferon plus ribavirin therapy, two 
protease inhibitors are also approved for the treatment of 
HCV genotype 1 patients. The protease inhibitors along 
with peg-interferon plus ribavirin showed better SVR 
than peg-interferon with ribavirin alone. Both inhibitors 
showed some adverse effects when given to HCV genotype 
1 patients. These inhibitors are not approved for the 
treatment of patients not having HCV genotype 1[12,39].
  Abbott is also working to develop interferon free drug 
combination for the treatment of patients living with HCV. 
In a mild stage trial, they gave a combination of protease 
inhibitor (ABT-450), NS5A inhibitor (ABT-267) and protease 
inhibitor (ABT-33) to HCV patients, and the rate of SVR 
observed was 87%. Abbott will soon start phase 栿 trials for 
this combination[40].
  Different nucleoside and non-nucleoside inhibitors 
targeting the HCV polymerase are at different phases of 
development (Table 1)[12]. The major advantage of nucleoside 
inhibitors is their pan-genotypic effect and high barrier to 
emergence of resistant mutant[12]. Nucleoside analogue GS-
7977 is a big hope for the patients living with HCV. GS-
7977 was administered in phase 栻 trials in a dose of 400 mg 
once daily plus ribavirin with and without peg interferon 
to HCV genotype 1, 2 & 3 patients. Approximately 88% 
SVR was achieved in treatment naive genotype 1 patients. 
The rate of SVR after 12 weeks administration of GS-
7977 plus ribavirin was higher as compared with 12 week 
administration of protease inhibitor with peg interferon plus 
ribavirin on treatment naive HCV genotype 1 patients. GS-
7977 plus ribavirin therapy showed a better response with 
both treatment naive and treatment experience patients of 
HCV genotypes 1, 2 & 3. To date no emergence of resistant 
mutant was observed. The phase 栿 trials showed that the 
GS-7977 showed a better response in patients living with 
different genotypes of HCV. The drug also showed very good 
response in non-responders of interferon therapy patients 
and patients with cirrhosis[12,41-43]. It is also expecting that 
GS-7977 therapy will replace Iiterferon therapy in 2015.
Table 1
Progress on HCV nucleoside and non-nucleoside inhibitors[12].
Drug name Company Target site Study phase
Valopictabine Idenix/Novartis Active site Stopped
IDX-184 Index Active site Partial hold
MK0608 Merck Active site Phase 栺
RG7128 Roche/Pharmaset Active site Phase 栻
R1626 Roche Active site Stopped
GS-7977 Pharmaset/Gilead Active site Phase 栿
BI207127 BoehringerIngelheim NNI 栺 Phase 栻
BILB-1941 BoehringerIngelheim NNI 栺 Stopped
MK-3281 Merck NNI 栺 Stopped
Filibuvir Pfizer NNI 栻 Phase 栻
VX-222 Vertex NNI 栻 Phase 栻
VCH-759 ViroChemPharma NNI 栻 Phase 栻
VCH-916 ViroChemPharma NNI 栻 Phase 栻
ABT-333 Abbott NNI 桇 Phase 栻
ABT-072 Abbott NNI 桇 Phase 栻
ANA-598 Anadys NNI 栿 Phase 栻
IDX-375 Index NNI 栿 Phase 栺
GSK-625433 GlaxcoSmithKline NNI 栿 Phase 栺
HCV-796 ViroPharma/Wyeth NNI 桇 Stopped
GS-9190 Gilead NNI 桇 Phase 栻
11. Conclusion
  Interferon plus ribavirin therapy produces a better response 
in patients living with HCV genotype 3. The major drawback 
of the therapy is a number of side effects. Interferon free 
Abbott’s triple therapy and GS-7977 drug are light of hope 
for the patients living with HCV.
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